Citi Maintains Buy Rating and $11 PT on Anthera Pharmaceuticals

A report from Citi reiterates its Buy rating and $11 price target on Anthera Pharmaceuticals ANTH. The report states, “This morning Anthera announced positive data from an interim BCell analysis of the PEARL-SC Study. Anthera continues to remain blinded to primary efficacy data. The data indicate that weekly and monthly subQ doses of A-623 (blisibimod) result in statistically significant reductions of B-cells. We view these results as positive, given that the findings are consistent with data from previous clinical studies of A-623.” ANTH closed yesterday at $5.82.